- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04156698
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
A Phase II, Single-center, Open-label, Single-arm Study of Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Hongli Gong, PhD.
- Phone Number: 8621-64377151
- Email: gonghlent@126.com
Study Contact Backup
- Name: Shu Tian, PhD.
- Phone Number: 8621-64377151
- Email: tianshueent@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200031
- Eye & ENT Hospital, Fudan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients have histologically confirmed hypopharyngeal squamous cell carcinoma and require total laryngectomy, including the piriform fossa, postcricoid region, and posterior pharyngeal wall with TNM stage cT3-4aN0-2M0(AJCC 7th).
- Able to understand and willing to sign a written informed consent document.
- Age≥ 18 and≤ 70 years.
- Male or female.
- Performance status of ECOG 0-2.
- Expected lifetime > 6 months.
- Normal blood test, hepatic and renal functions. Normal hearing. Blood test: WBC≥4.0×109/L,ANC≥2.0×109/L,PLT≥100×109/L,HGB≥100g/L;Hepatic function: ALT、AST< upper limit of normal. Kidney function: Serum creatinine < upper limit of normal value, and creatinine clearance rate ≥ 60 ml/min(Cockcroft-Gault formula). Cardiac ultrasonography left ventricular ejection fraction >50%.
- No prior allergic reaction to biological agents and/or ingredient in the drug.
- No drug abuse.
- Good compliance.
- No other important related diseases (such as other tumors, severe heart, lung and central nervous system diseases, etc.).
- Negative pregnancy test (for female patients with fertility).
- Male patients with fertility and female patients with fertility and pregnancy risk must agree to use contraceptive methods throughout the study period, and continued until at least 6 months after the last dose of cisplatin and 30 days after the last dose of PD-1 antibody/placebo (whichever occurs later). Female patients who do not have fertility (ie meet at least one of the following criteria): Have undergone hysterectomy and/or bilateral oophorectomy with archival records, medically confirmed ovarian function decline; In postmenopausal state. It is defined as: At least 12 months of continuous menstruation without other pathological or physiological reasons, and the status confirmed by serum follicle stimulating hormone (FSH) levels is consistent with postmenopausal status.
Exclusion Criteria:
- Patients with cervical lymph node cN3.
- Have a history of other cancers in the past five years, radical or untreated prostate cancer (Gleason score ≤ 6), or complete treatment of breast ductal carcinoma in situ, except for patients with cured skin basal cell carcinoma or squamous cell skin cancer.
- Patients with target lesions who have received radiation therapy or surgery (except biopsy).
- Patients who have previously used chemotherapy, immunotherapy, or biological targeted therapy for primary tumors
- Patients who have participated in other clinical trials within 4 weeks before the test.
- Any of the following conditions in the first 6 months of random grouping: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, patients with transient ischemic attack or symptomatic pulmonary embolism.
- Patients with hypertension who cannot control well through single antihypertensive medication (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg);
- Patients with grade I or above coronary heart disease, arrhythmia (including men with a QTc interval >450 ms, women >470 ms), and cardiac insufficiency.
- Urinary protein was greater than ++ and 24-hour urinary protein quantification >1.0 g.
- Many factors that affect oral medications (such as inability to swallow, nausea, vomiting, chronic diarrhea, and intestinal obstruction).
- Patients with abnormal coagulation function(INR>1.5、APTT>1.5 ULN)and bleeding tendency.
- Patients with a history of psychotropic substance abuse that is active or has a mental disorder.
- Patients who required systemic treatment with corticosteroids (>10 mg prednisone equivalent daily) or other immunosuppressive agents within 2 weeks prior to the first use of the study drug.
- Patients with a history of severe allergies or allergies; patients with active autoimmune diseases that may worsen when receiving immunostimulants; patients with type 1 diabetes, vitiligo, psoriasis, or hypothyroidism or hyperthyroidism who do not require immunosuppressive therapy are eligible to participate in the study.
- Patients who have previously been diagnosed with immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related diseases. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (HBV) surface antigen is positive at screening, or patients with positive HCV RNA [ribonucleic acid] when positive for anti-HCV antibody screening test.
- Vaccination within 4 weeks prior to randomization, except for inactivated vaccines.
- Pregnant or lactating women who are in the reproductive period but have not taken effective contraceptive measures.
- The investigator believes that it is inappropriate for individuals to participate in the trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including recent time [within the past year] or active suicidal ideation or behavior) .
- With a history of tuberculosis or antituberculosis treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Camrelizumab (PD-1 inhibitor) group
Induction chemotherapy combined with immunotherapy (TPF + Camrelizumab), q3w, 3 cycles in total: Docetaxel (domestic) 75 mg/m2 i.v. d1, Cisplatin 25 mg/m2 i.v. d1-3, Capecitabine 800 mg/m2 po bid d1-d14, Camrelizumab 200mg i.v. d1; Radical radiotherapy plus concurrent immunotherapy (CR or PR): Radiotherapy: Using intensity-modulated radiation therapy (IMRT). Primary site: GTV dose 66 (2.2Gy / fraction)-70 Gy (2Gy / fraction);CTV 1.6-1.9 Gy / fraction. Cervical lymph nodes: Radiotherapy plan is the same as the radiotherapy plan of original site; Concurrent immunotherapy : Camrelizumab 200mg i.v. d1, d22; Maintenance period: After completing concurrent chemoradiotherapy combined with immunotherapy, Camrelizumab 200 mg q3w will be given up to 12 months (calculated from the time of the first dose of PD-1 immunotherapy). |
Docetaxel is a chemotherapy drug.
Other Names:
Cisplatin is a chemotherapy drug.
Other Names:
Capecitabine is a chemotherapy drug.
Other Names:
Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: 9 weeks
|
The proportion of patients with partial and complete response as defined by RECIST 1.1 after induction therapy
|
9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: 3 years
|
Overall survival
|
3 years
|
PFS
Time Frame: 3 years
|
Progression free survival
|
3 years
|
LPR
Time Frame: 3 years
|
Larynx preservation rate
|
3 years
|
MFS
Time Frame: 3 years
|
Metastasis free survival
|
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Liang Zhou, PhD., Eye & ENT Hospital, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- zhouliang
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy
-
Hospices Civils de LyonCompletedChemotherapy Effect | G-CHOP Chemotherapy | R-CHOP ChemotherapyFrance
-
Taipei Medical UniversityCompletedChemotherapy TrainingTaiwan
-
University of RochesterTerminated
-
Universitaire Ziekenhuizen KU LeuvenFlemish League Against CancerCompletedCancer | ChemotherapyBelgium
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingChemotherapy EffectFrance
-
West Cancer CenterPfizer; Emory UniversityCompletedChemotherapy EffectUnited States
-
Taipei Medical UniversityTaipei Medical University WanFang HospitalCompleted
-
Milton S. Hershey Medical CenterCompleted
-
Xiamen Amoytop Biotech Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesCompleted
-
Queen's Medical CenterUniversity of Hawaii; Queen Emma Nursing Research InstituteCompleted
Clinical Trials on Docetaxel
-
Nereus Pharmaceuticals, Inc.CompletedCancerUnited States, Australia, India, Chile, Brazil, Argentina
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Zhuhai Beihai Biotech Co., LtdCompletedSolid Tumours | Bioequivalence | DocetaxelIndia
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaCompletedNon-Small Cell Lung Cancer (NSCLC)China
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center and other collaboratorsUnknownGastric CancerKorea, Republic of
-
Optimal Health ResearchCompletedBreast Cancer | Lung Cancer | Prostate CancerUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnCarcinoma, Non-Small-Cell Lung
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungJapan
-
SanofiCompleted
-
SanofiCompletedLung NeoplasmsFrance, Netherlands, Spain, Turkey, Belgium, Finland, Italy, United Kingdom